8 Pharmaceuticals Stocks to Sell Now

This week, the overall grades of 8 Pharmaceuticals stocks are lower, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

Jazz Pharmaceuticals Plc (JAZZ) is having a tough week. The company’s rating falls from a C to a D. Jazz Pharmaceuticals Plc is a specialty pharmaceutical company focused on developing and commercializing products to meet medical needs in neurology and psychiatry. The company also gets F’s in earnings momentum. For more information, get Portfolio Grader’s complete analysis of JAZZ stock.

This is a rough week for Valeant Pharmaceuticals International, Inc. (VRX). The company’s rating falls to D from the previous week’s C. Valeant Pharmaceuticals International, Inc. develops and distributes drugs. The company also gets F’s in earnings growth and earnings momentum. For more information, get Portfolio Grader’s complete analysis of VRX stock.

Dr. Reddy’s Laboratories Ltd. Sponsored ADR (RDY) declines this week from a C to a D. Dr. Reddy’s Laboratories Ltd. Sponsored ADR is a global company that produces and markets active pharmaceutical ingredients, intermediates, finished dosage forms, and biologic products. For more information, get Portfolio Grader’s complete analysis of RDY stock.

Lannett Company, Inc. (LCI) experiences a ratings drop this week, going from last week’s C to a D. Lannett Company, Inc. manufactures and distributes pharmaceutical products under its own trade name and under generic names. For more information, get Portfolio Grader’s complete analysis of LCI stock.

Nektar Therapeutics’ (NKTR) rating weakens this week, dropping to a D versus last week’s C. Nektar Therapeutics is a clinical-stage biopharmaceutical company which develops a pipeline of drug candidates that utilize company platforms. The company also gets F’s in sales growth, earnings growth, earnings surprise, earnings momentum, and return on equity. For more information, get Portfolio Grader’s complete analysis of NKTR stock.

XenoPort, Inc. (XNPT) slips from a C to a D this week. XenoPort, Inc. is a biopharmaceutical company that focuses on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. The company also gets F’s in sales growth, earnings growth, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of XNPT stock.

Endocyte, Inc. (ECYT) earns a F this week, moving down from last week’s grade of D. Endocyte, Inc. is a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases. The company also gets F’s in sales growth, operating margin growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of ECYT stock.

This week, Cipher Pharmaceuticals Inc. (CPHR) drops from a D to a F rating. The company also gets F’s in operating margin growth, earnings growth, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of CPHR stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2015/12/8-pharmaceuticals-stocks-to-sell-now/.

©2021 InvestorPlace Media, LLC